journal article·2024-11Open access

Integrated Biofilm Dispersion and Virulence Responsiveness for Targeted Treatment of Pseudomonas aeruginosa Infection in Lungs

Kristina Ivanova, Eva Ramon, Urszula Wnorowska, Katerina Todorova, Aleksandra Ivanova, Julio Bastos‐Arrieta, Antonio Puertas‐Segura, Piotr Deptula, Tsvetozara Damyanova, Tsvetelina Paunova‐Krasteva, Robert Bucki, Ivan Ivanov, Tzanko Tzanov

Advanced Functional Materials· Volume 34· Issue 46

Abstract

Abstract The self‐organization of microbes into biofilms provides multiple benefits including tolerance to mechanical stress and resistance to immune defences and antibiotics. Coupled to a compromised mucociliary function, these traits have dire consequences in cystic fibrosis patients – persistent infections are the main reason for morbidity and mortality. Thereby, disease progression is associated with universal colonization by Pseudomonas aeruginosa, which selects for a slimy phenotype to adapt to the lung microenvironment. Recognizing this, drug‐delivery vehicles that break down the mucoid extracellular matrix made of alginate are designed to enable better penetration and biofilm dispersion. In parallel, a protective layer responds to the proteolytic activity of the pathogen and thus controls drug availability. To realize this architecture, silica nanoparticles are loaded with imipenem, and then coated with elastin and alginate lyase in a layer‐by‐layer fashion using ultrasound. The nanoscale formulations eradicate up to 80% of the total biomass and reduce the bacterial viability in biofilms by 3 logs, considerably outperforming the bulk antibiotic in vitro, whereby the effects are correlated to changes in the viscoelasticity. Furthermore, the stimuli‐responsive nanocarriers are safe and effective in animal models of P. aeruginosa infection, presenting a considerable therapeutic promise in the challenging context of lung diseases.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Bacterial biofilms and quorum sensing · Antibiotic Resistance in Bacteria · Inhalation and Respiratory Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Group of Molecular and Industrial Biotechnology Department of Chemical Engineering Universitat Politècnica de Catalunya Rambla Sant Nebridi 22 Terrassa 08222 Spain

Department of Medical Microbiology and Nanobiomedical Engineering Medical University of Białystok Mickiewicza 2c Białystok 15–222 Poland

Institute of Experimental Morphology Pathology and Anthropology with Museum Bulgarian Academy of Sciences Acad. G. Bonchev, Bl. 25 Sofia 1113 Bulgaria

Stephan Angeloff Institute of Microbiology Bulgarian Academy of Sciences Acad. G. Bonchev, Bl. 26 Sofia 1113 Bulgaria

Funding

Agencia Estatal de Investigación

References (77)

Show source-provided references
1. 10.1016/j.ijantimicag.2004.02.01510.1016/j.ijantimicag.2004.02.015 ↗
2. 10.1016/S0140-6736(01)05321-110.1016/S0140-6736(01)05321-1 ↗
3. 10.1016/j.cmet.2019.06.00910.1016/j.cmet.2019.06.009 ↗
4. 10.1016/j.addr.2005.04.00710.1016/j.addr.2005.04.007 ↗
5. 10.1128/CMR.00040-0910.1128/CMR.00040-09 ↗
6. 10.1007/s40265-021-01635-610.1007/s40265-021-01635-6 ↗
7. 10.1038/s41522-022-00306-y10.1038/s41522-022-00306-y ↗
8. 10.3390/ijms14102098310.3390/ijms141020983 ↗
9. 10.1309/KJRPC7DD5TR9NTDM10.1309/KJRPC7DD5TR9NTDM ↗
10. 10.1016/j.progpolymsci.2011.06.00310.1016/j.progpolymsci.2011.06.003 ↗
11. 10.3390/jcm902051410.3390/jcm9020514 ↗
12. 10.1016/j.ijantimicag.2009.12.01110.1016/j.ijantimicag.2009.12.011 ↗
13. 10.1002/mbo3.14110.1002/mbo3.141 ↗
14. 10.1038/s41522-018-0056-310.1038/s41522-018-0056-3 ↗
15. Littlewood J. M. · UK Cyst. Fibros. Trust · 2009 · 1
16. 10.1177/204993611562170910.1177/2049936115621709 ↗
17. 10.1016/S1473-3099(17)30753-310.1016/S1473-3099(17)30753-3 ↗
18. 10.1159/00036953310.1159/000369533 ↗
19. 10.1186/1471-2180-10-14010.1186/1471-2180-10-140 ↗
20. 10.1016/j.jbc.2022.10235210.1016/j.jbc.2022.102352 ↗
21. 10.1007/s00253-020-10349-w10.1007/s00253-020-10349-w ↗
22. 10.3390/ijms2314763210.3390/ijms23147632 ↗
23. 10.1002/adfm.20200128410.1002/adfm.202001284 ↗
24. 10.1021/acsami.8b1494910.1021/acsami.8b14949 ↗
25. 10.1016/j.jcis.2023.04.18410.1016/j.jcis.2023.04.184 ↗
26. 10.1016/j.msec.2021.11251810.1016/j.msec.2021.112518 ↗
27. 10.1038/srep0993610.1038/srep09936 ↗
28. 10.1165/ajrcmb/4.1.2610.1165/ajrcmb/4.1.26 ↗
29. 10.1183/13993003.00769-202010.1183/13993003.00769-2020 ↗
30. 10.1183/13993003.01910-201710.1183/13993003.01910-2017 ↗
31. 10.1128/AAC.01789-1210.1128/AAC.01789-12 ↗
32. 10.1021/acsami.5b0421610.1021/acsami.5b04216 ↗
33. 10.1016/j.ces.2024.11973910.1016/j.ces.2024.119739 ↗
34. 10.1016/j.ultsonch.2017.05.01910.1016/j.ultsonch.2017.05.019 ↗
35. 10.1016/j.ultsonch.2016.04.03010.1016/j.ultsonch.2016.04.030 ↗
36. 10.1016/j.desal.2011.06.00110.1016/j.desal.2011.06.001 ↗
37. 10.1007/s00231-018-2517-x10.1007/s00231-018-2517-x ↗
38. 10.1126/science.aaa249110.1126/science.aaa2491 ↗
39. 10.1016/j.biotechadv.2018.11.01310.1016/j.biotechadv.2018.11.013 ↗
40. 10.1007/978-981-10-9026-4_110.1007/978-981-10-9026-4_1 ↗
41. 10.3389/fmicb.2019.0091310.3389/fmicb.2019.00913 ↗
42. 10.1021/acsami.7b0021710.1021/acsami.7b00217 ↗
43. 10.1128/jb.184.4.1140-1154.200210.1128/jb.184.4.1140-1154.2002 ↗
44. 10.3389/fmicb.2020.62081910.3389/fmicb.2020.620819 ↗
45. 10.1371/journal.pone.025297010.1371/journal.pone.0252970 ↗
46. 10.3389/fcimb.2021.82404210.3389/fcimb.2021.824042 ↗
47. 10.1016/j.ijmm.2010.08.00310.1016/j.ijmm.2010.08.003 ↗
48. 10.1073/pnas.140761611110.1073/pnas.1407616111 ↗
49. 10.1164/rccm.200609-1354OC10.1164/rccm.200609-1354OC ↗
50. 10.1126/science.295.5559.148710.1126/science.295.5559.1487 ↗
51. Le Roux M. · Elife · 2015 · 4
52. 10.3389/fcimb.2022.96932610.3389/fcimb.2022.969326 ↗
53. 10.1038/s41385-020-0270-110.1038/s41385-020-0270-1 ↗
54. 10.1016/j.bios.2007.05.00110.1016/j.bios.2007.05.001 ↗
55. 10.1016/j.colcom.2018.11.00710.1016/j.colcom.2018.11.007 ↗
56. 10.3390/microorganisms1104089210.3390/microorganisms11040892 ↗
57. 10.1038/s41598-018-28009-510.1038/s41598-018-28009-5 ↗
58. 10.1073/pnas.181178711510.1073/pnas.1811787115 ↗
59. 10.1371/journal.pone.008229710.1371/journal.pone.0082297 ↗
60. 10.2147/IDR.S34835710.2147/IDR.S348357 ↗
61. 10.3109/07388551.2012.67925010.3109/07388551.2012.679250 ↗
62. 10.1098/rsfs.2022.003210.1098/rsfs.2022.0032 ↗
63. 10.1098/rsfs.2022.003510.1098/rsfs.2022.0035 ↗
64. 10.1128/AAC.40.4.90410.1128/AAC.40.4.904 ↗
65. 10.1080/08927014.2011.55497710.1080/08927014.2011.554977 ↗
66. 10.1016/j.ymthe.2005.02.01010.1016/j.ymthe.2005.02.010 ↗
67. 10.2147/IJN.S27610510.2147/IJN.S276105 ↗
68. 10.1152/ajplung.00049.200310.1152/ajplung.00049.2003 ↗
69. 10.1039/C8NR00554K10.1039/C8NR00554K ↗
70. 10.1039/C5NR04119H10.1039/C5NR04119H ↗
71. 10.3389/fmicb.2021.61405810.3389/fmicb.2021.614058 ↗
72. 10.1016/j.isci.2023.10684310.1016/j.isci.2023.106843 ↗
73. 10.1038/s41578-021-00385-x10.1038/s41578-021-00385-x ↗
74. Clinical and Laboratory Standards Institute (CLSI) Clinical and Laboratory Standards Institute Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically Standard Approval CDM‐A. M07 Methods dilution Antimicrob. Susceptibility Tests Bact. That Grow Aerobically2018 91.
75. 10.1021/acsami.0c0936410.1021/acsami.0c09364 ↗
76. 10.1093/toxsci/55.1.2410.1093/toxsci/55.1.24 ↗
77. 10.3389/fcimb.2012.0016410.3389/fcimb.2012.00164 ↗